Expanded Access Program: Lanadelumab for the Prevention of Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Patients 2 to <12 Years of Age and Lanadelumab for the Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)

Shire20 个研究点分布在 5 个国家开始时间: 2020年10月12日最近更新: 2023年7月24日

适应症

试验速览

阶段: 不适用
状态: No Longer Available
发起方: Shire
试验地点: 20

研究概览入排标准研究者研究点记录与标识符相似试验

研究概览

简要总结

The expanded access program allows people to gain access to an unlicensed treatment on compassionate grounds. Lanadelumab, also known as TAK-743, is a medicine to help prevent angioedema attacks. This expanded access program enables these participants with a high unmet medical need to continue receiving lanadelumab during the interim period between completion of either the SHP643-301 (NCT04070326; SPRING study) or the TAK-743-3001 (NCT04444895) study and potential licensure of lanadelumab for the respective age group and/or treatment.

研究设计

研究类型: Expanded Access

入排标准

年龄范围: 2 Years 至 —（Child, Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•TAK-743-6001 Study (Acute Attacks of HAE):
•Pediatric participants, 2 to <12 years of age, with HAE who completed the SHP643-301 (SPRING) study and are deriving continued clinical benefit from lanadelumab treatment will be invited to take part in this program
•Participants have no suitable alternative treatment options and cannot enter a lanadelumab clinical trial
•Participant has a parent(s)/legal guardian who is informed of the nature of the expanded access program and can provide written informed consent for the child to participate (with assent from child when appropriate) prior to treatment
•Participants does not have any of the following liver function test abnormalities : alanine aminotransferase (ALT) greater than (>)3x upper limit of normal (ULN), or aspartate aminotransferase (AST) >3x ULN, or total bilirubin >2x ULN (unless the bilirubin elevation is a result of Gilbert's syndrome)
•Participant does not have any condition that in the opinion of the Investigator may compromise their safety
•Participant does not have a known hypersensitivity to lanadelumab or its components
•Participant (greater than or equal to >or=6 years) and/or caregiver is willing to self-administer lanadelumab at home and has received documented training on self-administration during the SHP643-301 (SPRING) Study
•For Female participants of childbearing potential only:
•Participant has agreed to be abstinent or agreed to comply with the applicable contraceptive requirements of this protocol for the duration of the expanded access program and for 70 days after completion
•Participant is not pregnant or breast-feeding Note: Participants who do not satisfy the above criteria will be excluded.
•TAK-743-5012 Study (Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)):
•Participant has completed the treatment period of the TAK-743-3001 study (all Visit 14 assessments have been completed).
•Participant is demonstrating continued benefit from lanadelumab treatment.
•Participant and/or a parent(s)/legal guardian is informed of the nature of the expanded access program and can provide written informed consent for themselves or the child to participate (with assent from child when appropriate) prior to treatment).
•Participant does not have any condition including lab test that in the opinion of the Investigator may compromise their safety.
•Participant does not have a known hypersensitivity to lanadelumab or its components.
•Participant and/or caregiver is willing to self-administer lanadelumab at home and has received documented training on self-administration during the Study TAK-743-3001 OR the participant and/or caregiver is willing to self-administer lanadelumab at home and will receive training at the first two dose administrations in accordance with protocol.
•Female Participants of childbearing potential only:
•Participant has agreed to be abstinent or agreed to comply with the applicable contraceptive requirements of this protocol for the duration of the expanded access program and for 70 days after completion of the last dose.
•Participant is not pregnant or breast-feeding.
•Male Participants only:
•Participant has agreed to comply with the applicable contraceptive requirements of this protocol for the duration of the expanded access program and for 70 days following the last dose of lanadelumab
•Participant has agreed to not donate sperm during the course of the program and for 70 days following the last dose of lanadelumab.

排除标准

未提供

研究者

发起方

Shire

申办方类型

Industry

责任方

Sponsor

研究点 (20)

Loading locations...

相似试验

No Longer Available

不适用

Expanded Access to TAK-113 for Adults With Metastatic Colorectal Cancer (mCRC)Colorectal Cancer

NCT06195514Takeda

No Longer Available

不适用

Expanded Access to ElezanumabAcute Spinal Cord Injury (SCI)

NCT04278235AbbVie

已完成

3 期

Expanded Access Program With Lanadelumab for Japanese People With Hereditary AngioedemaHereditary Angioedema

NCT04687137Takeda12

No Longer Available

不适用

Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)Multiple System Atrophy (MSA)

NCT05086094Biohaven Pharmaceuticals, Inc.

Approved For Marketing

不适用

Donidalorsen Expanded Access Program for Patients With Hereditary AngioedemaHereditary Angioedema

NCT06415448Ionis Pharmaceuticals, Inc.